| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Biomolecular Sciences, University of Manchester Institute of Science and Technology, Manchester M60 1QD, United Kingdom [F. H.]; Laboratory of Molecular Oncology, Strang Cancer Prevention Center, New York, New York 10021 [C. C., A. N. A. M.]; Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom [D. B.]; and Department of Cell Biology, Weill Medical College of Cornell University, New York, New York 10021 [A. N. A. M.]
The breast and ovarian cancer susceptibility gene product BRCA1 is a tumor suppressor, but its precise biochemical function remains unknown. The BRCA1 COOH terminus acts as a transcription activation domain, and germ-line cancer- predisposing mutations in this region abolish transcription activation, whereas benign polymorphisms do not. These results raise the possibility that loss of transcription activation by BRCA1 is crucial for oncogenesis. Therefore, identification of residues involved in transcription activation by BRCA1 will help understand why particular germ-line missense mutations are deleterious and may provide more reliable presymptomatic risk assessment.
The BRCA1 COOH terminus (amino acids 15601863) consists of two BRCTspreceded by a region likely to be nonglobular. We combined site-directed and random mutagenesis, followed by a functional transcription assay in yeast: (a) error-prone PCR-induced random mutagenesis generated eight unique missense mutations causing loss of function, six of which targeted hydrophobic residues conserved in canine, mouse, rat, and human BRCA1; (b) random insertion of a variable pentapeptide cassette generated 21 insertion mutants. All pentapeptide insertions NH2-terminal to the BRCTs retained wild-type activity, whereas insertions in the BRCTs were, with few exceptions, deleterious; and (c) site-directed mutagenesis was used to characterize five known germ-line mutations and to perform deletion analysis of the COOH terminus. Deletion analysis revealed that the integrity of the most COOH-terminal hydrophobic cluster (I1855, L1854, and Y1853) is necessary for activity. We conclude that the integrity of the BRCT domains is crucial for transcription activation and that hydrophobic residues may be important for BRCT function. Therefore, the yeast-based assay for transcription activation can be used successfully to provide tools for structure-function analysis of BRCA1 and may form the basis of a BRCA1 functional assay.
This article has been cited by other articles:
![]() |
K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pajunen, H. Turakainen, E. Poussu, J. Peranen, M. Vihinen, and H. Savilahti High-precision mapping of protein protein interfaces: an integrated genetic strategy combining en masse mutagenesis and DNA-level parallel analysis on a yeast two-hybrid platform Nucleic Acids Res., August 15, 2007; (2007) gkm563v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Carvalho, S. M. Marsillac, R. Karchin, S. Manoukian, S. Grist, R. F. Swaby, T. P. Urmenyi, E. Rondinelli, R. Silva, L. Gayol, et al. Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis Cancer Res., February 15, 2007; 67(4): 1494 - 1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Chenevix-Trench, S. Healey, S. Lakhani, P. Waring, M. Cummings, R. Brinkworth, A. M. Deffenbaugh, L. A. Burbidge, D. Pruss, T. Judkins, et al. Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance Cancer Res., February 15, 2006; 66(4): 2019 - 2027. [Abstract] [Full Text] [PDF] |
||||
![]() |
C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij, et al. Classification of BRCA1 missense variants of unknown clinical significance J. Med. Genet., February 1, 2005; 42(2): 138 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Figge and L. Blankenship Missense Mutations in the BRCT Domain of BRCA-1 from High-Risk Women Frequently Perturb Strongly Hydrophobic Amino Acids Conserved among Mammals Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 1037 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mirkovic, M. A. Marti-Renom, B. L. Weber, A. Sali, and A. N. A. Monteiro Structure-Based Assessment of Missense Mutations in Human BRCA1: Implications for Breast and Ovarian Cancer Predisposition Cancer Res., June 1, 2004; 64(11): 3790 - 3797. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Williams, D. I. Chasman, D. D. Hau, B. Hui, A. Y. Lau, and J. N. M. Glover Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations J. Biol. Chem., December 26, 2003; 278(52): 53007 - 53016. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lingaas, K. E. Comstock, E. F. Kirkness, A. Sorensen, T. Aarskaug, C. Hitte, M. L. Nickerson, L. Moe, L. S. Schmidt, R. Thomas, et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog Hum. Mol. Genet., December 1, 2003; 12(23): 3043 - 3053. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Fleming, J. D. Potter, C. J. Ramirez, G. K. Ostrander, and E. A. Ostrander Understanding missense mutations in the BRCA1 gene: An evolutionary approach PNAS, February 4, 2003; 100(3): 1151 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Robert, F. Hayes, A. Lazdunski, and G. P. F. Michel Identification of XcpZ Domains Required for Assembly of the Secreton of Pseudomonas aeruginosa J. Bacteriol., March 15, 2002; 184(6): 1779 - 1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vallon-Christersson, C. Cayanan, K. Haraldsson, N. Loman, J. T. Bergthorsson, K. Brondum-Nielsen, A.-M. Gerdes, P. Moller, U. Kristoffersson, H. Olsson, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families Hum. Mol. Genet., February 1, 2001; 10(4): 353 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Houvras, M. Benezra, H. Zhang, J. J. Manfredi, B. L. Weber, and J. D. Licht BRCA1 Physically and Functionally Interacts with ATF1 J. Biol. Chem., November 10, 2000; 275(46): 36230 - 36237. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyake, Y.-F. Hu, D. S. Yu, and R. Li A Functional Comparison of BRCA1 C-terminal Domains in Transcription Activation and Chromatin Remodeling J. Biol. Chem., December 15, 2000; 275(51): 40169 - 40173. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |